Risks between BCL and TCL by demographic characteristics and lymphoma subtypes, 17 SEER registry areas, 2000 to 2016, with follow-up through 2017
| . | Risk of TCL following BCL* . | Risk of BCL following TCL† . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | No. of BCL patients . | Observed no. of TCLs . | SIR . | (95% CI) . | Mean PY at risk . | Mean age at BCL . | No. of TCL patients . | Observed no. of BCLs . | SIR . | (95% CI) . | Mean PY at risk . | Mean age at TCL . |
| Total, N | 288 478 | 354 | 4.7 | (4.2, 5.2) | 5.5 | 62 | 23 747 | 300 | 4.7 | (4.1, 5.2) | 4.9 | 54 |
| Sex | ||||||||||||
| Male | 159 759 | 232 | 4.7 | (4.1, 5.3) | 5.4 | 61 | 14 098 | 198 | 4.6 | (4.0, 5.3) | 4.7 | 53 |
| Female | 128 719 | 122 | 4.7 | (3.9, 5.6) | 5.7 | 64 | 9649 | 102 | 4.7 | (3.8, 5.7) | 5.1 | 56 |
| Age at first primary lymphoma, y | ||||||||||||
| <60 | 115 559 | 144 | 6.8 | (5.8, 8.0) | 7.1 | 44 | 13 130 | 119 | 6.3 | (5.2, 7.5) | 5.8 | 39 |
| ≥60 | 172 919 | 210 | 3.9 | (3.4, 4.4) | 4.5 | 74 | 10 617 | 181 | 4.0 | (3.4, 4.6) | 3.7 | 73 |
| Time since first lymphoma diagnosis, y | ||||||||||||
| <1 | 288 478 | 87 | 7.3 | (5.9, 9.0) | 0.9 | 62 | 23 747 | 111 | 10.5 | (8.7, 12.7) | 0.8 | 54 |
| 1-4.9 | 234 412 | 168 | 5.0 | (4.3, 5.8) | 3.0 | 60 | 17 521 | 105 | 3.9 | (3.2, 4.8) | 2.9 | 51 |
| ≥5 | 130 725 | 99 | 3.3 | (2.7, 4.0) | 4.8 | 57 | 9100 | 84 | 3.1 | (2.5, 3.8) | 5.0 | 49 |
| Year of first primary lymphoma diagnosis | ||||||||||||
| 2000-2005 | 93 556 | 126 | 3.6 | (3.0, 4.3) | 8.0 | 61 | 7218 | 121 | 3.9 | (3.2, 5.0) | 7.3 | 55 |
| 2006-2011 | 103 906 | 154 | 5.3 | (4.5, 6.2) | 5.8 | 62 | 8405 | 104 | 4.4 | (3.6, 5.0) | 5.1 | 54 |
| 2012-2016 | 91 016 | 74 | 6.4 | (5.0, 8.0) | 2.6 | 63 | 8124 | 75 | 7.8 | (6.2,10.0) | 2.4 | 53 |
| First primary lymphoma subtype | ||||||||||||
| HL | 33 402 | 72 | 13.9 | (10.9, 17.6) | 7.3 | 40 | NA | NA | NA | NA | NA | NA |
| DLBCL | 80 155 | 96 | 5.5 | (4.5, 6.7) | 4.5 | 64 | NA | NA | NA | NA | NA | NA |
| FL | 42 360 | 39 | 3.0 | (2.1, 4.1) | 6.4 | 63 | NA | NA | NA | NA | NA | NA |
| CLL/SLL | 67 008 | 74 | 3.3 | (2.6, 4.1) | 5.5 | 69 | NA | NA | NA | NA | NA | NA |
| MZL | 21 626 | 38 | 5.8 | (4.1, 7.9) | 6.0 | 65 | NA | NA | NA | NA | NA | NA |
| MF | NA | NA | NA | NA | NA | NA | 5960 | 84 | 3.4 | (2.7, 4.2) | 6.6 | 56 |
| PTCL-NOS | NA | NA | NA | NA | NA | NA | 4669 | 56 | 6.2 | (4.7, 8.0) | 3.1 | 61 |
| AITL | NA | NA | NA | NA | NA | NA | 1587 | 28 | 7.1 | (4.7, 10.3) | 3.2 | 66 |
| ALCL | NA | NA | NA | NA | NA | NA | 2844 | 23 | 4.0 | (2.5, 6.0) | 5.1 | 49 |
| CTCL | NA | NA | NA | NA | NA | NA | 3717 | 83 | 5.3 | (4.2, 6.6) | 6.2 | 59 |
| . | Risk of TCL following BCL* . | Risk of BCL following TCL† . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | No. of BCL patients . | Observed no. of TCLs . | SIR . | (95% CI) . | Mean PY at risk . | Mean age at BCL . | No. of TCL patients . | Observed no. of BCLs . | SIR . | (95% CI) . | Mean PY at risk . | Mean age at TCL . |
| Total, N | 288 478 | 354 | 4.7 | (4.2, 5.2) | 5.5 | 62 | 23 747 | 300 | 4.7 | (4.1, 5.2) | 4.9 | 54 |
| Sex | ||||||||||||
| Male | 159 759 | 232 | 4.7 | (4.1, 5.3) | 5.4 | 61 | 14 098 | 198 | 4.6 | (4.0, 5.3) | 4.7 | 53 |
| Female | 128 719 | 122 | 4.7 | (3.9, 5.6) | 5.7 | 64 | 9649 | 102 | 4.7 | (3.8, 5.7) | 5.1 | 56 |
| Age at first primary lymphoma, y | ||||||||||||
| <60 | 115 559 | 144 | 6.8 | (5.8, 8.0) | 7.1 | 44 | 13 130 | 119 | 6.3 | (5.2, 7.5) | 5.8 | 39 |
| ≥60 | 172 919 | 210 | 3.9 | (3.4, 4.4) | 4.5 | 74 | 10 617 | 181 | 4.0 | (3.4, 4.6) | 3.7 | 73 |
| Time since first lymphoma diagnosis, y | ||||||||||||
| <1 | 288 478 | 87 | 7.3 | (5.9, 9.0) | 0.9 | 62 | 23 747 | 111 | 10.5 | (8.7, 12.7) | 0.8 | 54 |
| 1-4.9 | 234 412 | 168 | 5.0 | (4.3, 5.8) | 3.0 | 60 | 17 521 | 105 | 3.9 | (3.2, 4.8) | 2.9 | 51 |
| ≥5 | 130 725 | 99 | 3.3 | (2.7, 4.0) | 4.8 | 57 | 9100 | 84 | 3.1 | (2.5, 3.8) | 5.0 | 49 |
| Year of first primary lymphoma diagnosis | ||||||||||||
| 2000-2005 | 93 556 | 126 | 3.6 | (3.0, 4.3) | 8.0 | 61 | 7218 | 121 | 3.9 | (3.2, 5.0) | 7.3 | 55 |
| 2006-2011 | 103 906 | 154 | 5.3 | (4.5, 6.2) | 5.8 | 62 | 8405 | 104 | 4.4 | (3.6, 5.0) | 5.1 | 54 |
| 2012-2016 | 91 016 | 74 | 6.4 | (5.0, 8.0) | 2.6 | 63 | 8124 | 75 | 7.8 | (6.2,10.0) | 2.4 | 53 |
| First primary lymphoma subtype | ||||||||||||
| HL | 33 402 | 72 | 13.9 | (10.9, 17.6) | 7.3 | 40 | NA | NA | NA | NA | NA | NA |
| DLBCL | 80 155 | 96 | 5.5 | (4.5, 6.7) | 4.5 | 64 | NA | NA | NA | NA | NA | NA |
| FL | 42 360 | 39 | 3.0 | (2.1, 4.1) | 6.4 | 63 | NA | NA | NA | NA | NA | NA |
| CLL/SLL | 67 008 | 74 | 3.3 | (2.6, 4.1) | 5.5 | 69 | NA | NA | NA | NA | NA | NA |
| MZL | 21 626 | 38 | 5.8 | (4.1, 7.9) | 6.0 | 65 | NA | NA | NA | NA | NA | NA |
| MF | NA | NA | NA | NA | NA | NA | 5960 | 84 | 3.4 | (2.7, 4.2) | 6.6 | 56 |
| PTCL-NOS | NA | NA | NA | NA | NA | NA | 4669 | 56 | 6.2 | (4.7, 8.0) | 3.1 | 61 |
| AITL | NA | NA | NA | NA | NA | NA | 1587 | 28 | 7.1 | (4.7, 10.3) | 3.2 | 66 |
| ALCL | NA | NA | NA | NA | NA | NA | 2844 | 23 | 4.0 | (2.5, 6.0) | 5.1 | 49 |
| CTCL | NA | NA | NA | NA | NA | NA | 3717 | 83 | 5.3 | (4.2, 6.6) | 6.2 | 59 |
ALCL, anaplastic large cell lymphoma; CTCL, cutaneous T-cell lymphoma; ER, excess risk; NA, not applicable; PY, person-year.
ICD-O-3 codes included in the category of BCL: (HL; 9651, 9652, 9653-9655, 9663-9667, 9650, 9661-9662), (DLBCL; 9680, 9684, 9678), (FL; 9690-9691, 9695, 9698), (CLL/SLL; 9670, 9823), (MZL; 9689, 9699, 9760, 9764, 9699), 9659, 9832, 9673, 9671, 9761, 9679, 9687, 9826, 9940, 9591, 9675.
ICD-O-3 codes included in the category of TCL: (MF/SS; 9700, 9701), (PTCL-NOS; 9702, 9675), (AITL; 9705), (ALCL; 9714), (CTCL; 9709, 9718), 9708, 9716, 9717, 9827, 9719, 9948, 9831, 9834, 9832, 9591, 9684.